Keryx Biopharmaceuticals Inc (KERX) Financial Statements (2024 and earlier)

Company Profile

Business Address ONE MARINA PARK DR.
BOSTON, MA 02210
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2018
MRQ
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 93,526111,810200,29085,79255,69614,677
Cash and cash equivalents 93,526111,810200,29074,28455,69614,677
Short-term investments    11,508  
Receivables 8,1465,2364,293882  
Inventory, net of allowances, customer advances and progress billings 28,69512,68141,8817,830
Inventory 28,69512,68141,8817,830  
Prepaid expense and other current assets430
Other current assets 11,1993,1702,8304,0921,232
Total current assets: 141,566132,897249,29498,59656,92815,107
Noncurrent Assets
Property, plant and equipment 4,5214,2115,0831,53234956
Intangible assets, net (including goodwill) 3,2083,2083,2082,8562,8562,856
Goodwill 3,2083,2083,2083,2083,2083,208
Intangible assets, net (excluding goodwill)    (352)(352)(352)
Other noncurrent assets 9,5771,1111,100292281
Prepaid expense and other noncurrent assets198
Other undisclosed noncurrent assets    352352352
Total noncurrent assets: 17,3068,5309,3915,0323,8383,462
TOTAL ASSETS: 158,872141,427258,685103,62860,76618,569
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 45,03121,19021,32224,14614,0047,212
Employee-related liabilities 7,5048,1905,4734,7511,324827
Accounts payable 6,4742,225    
Accrued liabilities 21,86310,775244   
Other undisclosed accounts payable and accrued liabilities 9,190 15,60519,39512,6806,385
Derivative instruments and hedges, liabilities   46,686   
Deferred revenue and credits  3,526414  
Other liabilities 145117355   
Other undisclosed current liabilities 2442445,7174,7511,324827
Total current liabilities: 45,42021,55177,60629,31115,3288,039
Noncurrent Liabilities
Long-term debt and lease obligation 125,000125,00090,773   
Long-term debt, excluding current maturities 125,000125,00090,773   
Liabilities, other than long-term debt 1,9122,3023,3728333836
Deferred revenue and credits1,0181,2621,506   
Deferred tax liabilities, net   790700  
Other liabilities 8941,0401,0761333836
Other undisclosed noncurrent liabilities 635870    
Total noncurrent liabilities: 127,547128,17294,1458333836
Total liabilities: 172,967149,723171,75130,14415,3668,075
Equity
Equity, attributable to parent (14,095)(8,296)86,93473,48445,40010,494
Common stock 119106105938372
Treasury stock, value (357)(357)(357)(357)(357)(357)
Additional paid in capital 984,681827,053761,189624,606485,014403,387
Accumulated deficit (998,538)(835,098)(674,003)(550,858)(439,340)(392,608)
Total equity: (14,095)(8,296)86,93473,48445,40010,494
TOTAL LIABILITIES AND EQUITY: 158,872141,427258,685103,62860,76618,569

Income Statement (P&L) ($ in thousands)

9/30/2018
TTM
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Revenues 60,64131,98313,68011,7257,000166
Revenue, net60,64131,98313,68011,7257,161166
Cost of revenue
(Cost of Goods and Services Sold)
 (3,467)(27,968)(2,600)(495)  
Gross profit: 57,1744,01511,08011,2307,000166
Operating expenses (162,332)(154,746)(124,748)(122,054)(54,083)(27,079)
Other undisclosed operating income (loss) 3,46727,9682,600(405) (166)
Operating loss: (101,691)(122,763)(111,068)(111,229)(47,083)(27,079)
Nonoperating income (expense) (61,984)(38,252)(11,987)4113511,719
Other nonoperating income (expense) 981(4,025)(11,987)4113511,719
Interest and debt expense (63,000)(34,209)(11,357)   
Other undisclosed income from continuing operations before equity method investments, income taxes 63,00034,20911,357   
Loss from continuing operations before income taxes: (163,675)(161,015)(123,055)(110,818)(46,732)(25,360)
Income tax expense (benefit) 235(80)(90)(700) 15,190
Loss from continuing operations: (163,440)(161,095)(123,145)(111,518)(46,732)(10,170)
Loss before gain (loss) on sale of properties: (163,440)(161,095)(123,145)(111,518)(46,732)(10,170)
Net loss: (163,440)(161,095)(123,145)(111,518)(46,732)(10,170)
Other undisclosed net loss attributable to parent      (12,551)
Net loss available to common stockholders, diluted: (163,440)(161,095)(123,145)(111,518)(46,732)(22,721)

Comprehensive Income ($ in thousands)

9/30/2018
TTM
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net loss: (163,440)(161,095)(123,145)(111,518)(46,732)(10,170)
Comprehensive loss: (163,440)(161,095)(123,145)(111,518)(46,732)(10,170)
Other undisclosed comprehensive loss, net of tax, attributable to parent      (12,551)
Comprehensive loss, net of tax, attributable to parent: (163,440)(161,095)(123,145)(111,518)(46,732)(22,721)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: